Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00085904
Status:
COMPLETED
Last Update Posted:
2008-10-13
First Post:
2004-06-16
Brief Title:
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
Sponsor:
Organization:
GlaxoSmithKline